08:38 AM EDT, 07/09/2025 (MT Newswires) -- Revive Therapeutics ( RVVTF ) late on Tuesday said the research study assessing Bucillamine as a potential treatment for nerve agent exposure -- conducted in collaboration with Defence R&D Canada, Suffield Research Centre (DRDC) -- will continue through September.

DRDC, part of the Canadian Department of National Defence, is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.

Shares of the company closed unchanged at $0.020 on Tuesday on the Canadian Securities Exchange.